BETHESDA, Md., Sept. 17 /PRNewswire/ -- United BioSource Corporation (UBC) today announced the acquisition of Caro Research, Inc., a leading provider of simulation technologies that help pharmaceutical and life science companies assess costs and benefits associated with health care. With extensive knowledge of cost data sources and population databases, Caro's team has established methods of collecting, handling and analyzing cost and clinical data to support the development and commercialization of drugs, devices, diagnostics and procedures. The acquisition of Caro Research continues UBC's commitment to invest in technology and scientific leadership to support its clients in meeting the increasing requirements for real-world evidence.
"Caro Research is the unquestioned leader in simulation modeling applied to the issues of value and safety of medical products," said UBC's CEO Ethan Leder. "These techniques, at the forefront of health care decision making, give innovative companies the ability to project how their product will perform in the real world from both an economic and clinical perspective." Leder continued, "We are proud to have Dr. Caro and his team of distinguished scientists and technologists join our health care analytics team. In addition to leading-edge scientific capability, Caro Research expands our scientific presence in the European, Canadian and Latin American markets."
"UBC is an ideal fit with the mission and capabilities of Caro Research," said Jaime Caro, MD, founder and CEO of Caro Research. "Our organizations know and respect each other from working collaboratively on many projects. Together, we can capitalize on UBC's reach, resources and scientific expertise to meet the exploding demand for our technology, analytical and data services."
Dr. Caro will be respons
|SOURCE United BioSource Corporation|
Copyright©2007 PR Newswire.
All rights reserved